By Chibuike Oguh NEW YORK (Reuters) -Shares of AT&T Inc fell nearly 7% to hit their lowest level in thirty…
Category: Health
Acumen’s Alzheimer’s drug passes initial safety test
By Julie Steenhuysen CHICAGO (Reuters) – An experimental Alzheimer’s disease drug developed by Acumen Pharmaceuticals targeting a novel form of…
Biden’s pick for top U.S. general warns on Republican blocking promotions
By Phil Stewart and Patricia Zengerle WASHINGTON (Reuters) -President Joe Biden’s nominee to become the top U.S. general warned on…
As earnings loom, investors weigh recession resilience
By David Randall NEW YORK (Reuters) -As second-quarter earnings approach, investors are looking at beaten-down sectors which might gain ground…
US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug
By Deena Beasley and Julie Steenhuysen LOS ANGELES (Reuters) -Eisai and Biogen’s Leqembi won a coveted standard approval nod from…
US wants coalition of nations to engage China in curbing synthetic drugs
By Michael Martina and Simon Lewis WASHINGTON (Reuters) – The U.S. wants other countries to engage China on limiting the…
Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease
By Ludwig Burger (Reuters) -Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5…
Novartis’ Sandoz wagers its standalone future on biosimilar success
By Natalie Grover LONDON (Reuters) – Novartis’ soon-to-be spun off generics division Sandoz is betting on biosimilars, copies of high-priced…
Roche looking to sell or shut down California biologic drug plant
(This May 31 story has been corrected to fix the spelling of executive’s name to Teresa, not Theresa, in paragraph…
AstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients
By Natalie Grover LONDON (Reuters) – AstraZeneca’s lung cancer therapy, Tagrisso, cut the risk of death by more than half…